ALNYLAM PHARMACEUTICALS, INC. Income Statement
ALNY / Health Care|15 years of annual SEC 10-K data (FY2011-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 15 fiscal years. All figures from audited SEC 10-K filings.
ALNYLAM PHARMACEUTICALS, INC. reported $3.7B in revenue and $18M in net loss for FY2025. Revenue has grown at a 62.4% compound annual rate over the past 9 years.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score 0.37 (distress zone, below 1.8 threshold)
- Negative profit margin: -12.4%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.7B | $2.2B | $1.8B | $1.0B | $844.3M | $492.9M | $89.9M | $74.9M | $89.9M | $47.2M | - | - | - | - | - |
| Cost of Revenue | $677.2M | $306.5M | $268.2M | $140.2M | $115.0M | $74.2M | $0 | $1.8M | $0 | - | - | - | - | - | - |
| SG&A Expense | $1.2B | $975.5M | $795.6M | $770.7M | $620.6M | $588.4M | $199.4M | $382.4M | $199.4M | $89.4M | $60.6M | $44.5M | $27.2M | $44.6M | $38.3M |
| R&D Expense | $1.3B | $1.1B | $1.0B | $883.0M | $792.2M | $654.8M | $390.6M | $505.4M | $390.6M | $382.4M | $276.5M | $190.2M | $113.0M | $86.6M | $99.3M |
| Operating Income | $501.6M | -$176.9M | -$282.2M | -$785.1M | -$708.7M | -$828.4M | -$500.1M | -$814.7M | -$500.1M | -$424.6M | -$296.0M | -$405.0M | -$92.9M | -$129.5M | -$54.8M |
| Interest Expense | - | - | $121.2M | $156.0M | $143.0M | $84.5M | - | $0 | - | - | - | - | - | - | - |
| Income Tax | $9.4M | -$99.2M | $6.7M | $4.2M | $680.0K | $2.7M | $0 | $823.0K | $0 | $0 | $0 | -$40.2M | -$2.7M | -$10.6M | $0 |
| Net Income | -$18.3M | -$278.2M | -$440.2M | -$1.1B | -$852.8M | -$858.3M | -$490.9M | -$761.5M | -$490.9M | -$410.1M | -$290.1M | -$360.4M | -$89.2M | -$106.0M | -$57.6M |
| EPS (Basic) | -$3.52 | -$2.18 | -$3.52 | -$9.30 | -$7.20 | -$7.46 | - | - | - | - | - | - | - | - | - |
| EPS (Diluted) | -$3.52 | -$2.18 | -$3.52 | -$9.30 | -$7.20 | -$7.46 | -$5.42 | -$7.57 | - | - | - | - | - | - | - |
| Shares Outstanding | 129.3M | 129.3M | 125.8M | 123.9M | 120.2M | 116.4M | 101.2M | 101.2M | 90.6M | 85.6M | 84.0M | 74.3M | 61.6M | 50.3M | 42.4M |
| Operating Margin | 13.5% | -7.9% | -15.4% | -75.7% | -83.9% | -168.1% | -556.2% | -1087.6% | - | - | - | - | - | - | - |
| Profit Margin | -0.5% | -12.4% | -24.1% | -109.0% | -101.0% | -174.2% | -546.0% | -1016.6% | - | - | - | - | - | - | - |